** BMO Capital Markets starts Novo Nordisk's U.S.-listed shares with "outperform" and a Street-high PT of $163, per LSEG data
** The Danish drugmaker' stock gains 1% to $126.66 after the EU drug regulator found no evidence that a class of diabetes and weight-loss drugs such as Novo's hugely popular Wegovy, are linked to suicidal thoughts
** BMO says "Our in-depth analysis of the growing obesity and adjacent metabolic disease market suggests both Lilly and Novo will remain the two entrenched players in this duopoly"
** BMO raises Eli Lilly's PT to $900
** Says Novo's expanded manufacturing with Catalent allows it to continue to supply the capacity-constrained market
** Adds NVO's multiple in-development obesity assets have strengthened its pipeline in a market the brokerage sees growing to over $130 billion in the U.S.
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Comments